MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Operating Income 2011-2026 | BHC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 963 M | 454 M | 450 M | 676 M | -203 M | -2.38 B | 102 M | -566 M | 1.53 B | 2 B | -410 M | 79.7 M | 300 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2 B | -2.38 B | 230 M |
Quarterly Operating Income Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 389 M | 281 M | - | 14 M | 412 M | 175 M | - | 244 M | 161 M | 285 M | - | 574 M | -270 M | -221 M | -5 M | 460 M | -27 M | 248 M | -1.08 B | 329 M | 257 M | 287 M | 25 M | 117 M | -245 M | -2.28 B | -322 M | 38 M | 175 M | 211 M | 150 M | -863 M | 81 M | 66 M | 168 M | 448 M | 342 M | 569 M | 617 M | 672 M | 355 M | 357 M | - | -892 M | 142 M | 117 M | - | 29.5 M | 86.8 M | 61.5 M | - | 112 M | 118 M | 74.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 672 M | -2.28 B | 63.5 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M |  USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.18 | 3.07 % | $ 127 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.3 | 1.87 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 12.3 | -0.49 % | $ 630 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.52 | -0.14 % | $ 2.05 B |  France |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 4.92 | -5.01 % | $ 648 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 25.08 | -3.09 % | $ 1.16 B | USA |
 |
Evolus
EOLS
|
-34.4 M | $ 6.69 | 0.6 % | $ 415 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 47.88 | -2.29 % | $ 1.56 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.23 | 1.64 % | $ 21.5 M |  China |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.68 | 1.14 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.57 | -1.8 % | $ 4.43 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.72 | 2.08 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.85 | -3.27 % | $ 54.1 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.18 | 1.87 % | $ 294 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.86 | 1.99 % | $ 20.1 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 13.86 | -0.47 % | $ 1.9 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | $ 0.45 | 0.36 % | $ 7.13 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.16 | -14.44 % | $ 5 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.55 | -5.8 % | $ 137 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 9.3 | 2.54 % | $ 661 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.49 | -2.66 % | $ 224 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.62 | -1.96 % | $ 29.7 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 9.43 | 4.37 % | $ 5.83 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.62 | -0.61 % | $ 16.9 M | USA |
 |
Viatris
VTRS
|
1.61 B | $ 12.36 | -0.76 % | $ 15 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |